

## Centessa Pharmaceuticals to Participate in TD Cowen's 44th Annual Health Care Conference

February 22, 2024

BOSTON and LONDON, Feb. 22, 2024 (GLOBE NEWSWIRE) -- <u>Centessa Pharmaceuticals plc</u> (Nasdaq: CNTA), a clinical-stage pharmaceutical company that aims to discover and develop transformational medicines for patients, today announced that members of its management team will participate in TD Cowen's 44 <sup>th</sup> Annual Health Care Conference in Boston, MA. A fireside chat is scheduled for Tuesday, March 5<sup>th</sup> at 2:50 PM ET.

The live audio webcast of this event, as well as an archived recording, will be available under the "Events and Publications" tab on the investor relations section of the Centessa Pharmaceuticals website at <a href="https://investors.centessa.com/events-presentations">https://investors.centessa.com/events-presentations</a>.

## **About Centessa Pharmaceuticals**

Centessa Pharmaceuticals plc is a clinical-stage pharmaceutical company that aims to discover and develop transformational medicines for patients. Our most advanced programs include a hemophilia program, an orexin agonist program for the treatment of narcolepsy and other sleep-wake disorders and an immuno-oncology program focused on our LockBody® technology platform. We operate with the conviction that each one of our programs has the potential to change the current treatment paradigm and establish a new standard of care. For more information, visit <a href="https://www.centessa.com">www.centessa.com</a>, which does not form part of this release.

## Contact

Kristen K. Sheppard, Esq. SVP of Investor Relations investors@centessa.com